Clinigen signs exclusive agreement with Eyevance Pharmaceuticals to supply and distribute NATACYN® (natamycin) in several markets outside the US

Clinigen Group plc (AIM: CLIN, 'Clinigen'), the global pharmaceutical Products and Services company, announces it has signed an exclusive agreement to partner with Eyevance Pharmaceuticals, a wholly-owned subsidiary of Santen Pharmaceutical Co., LTD, to manage the supply and distribution of NATACYN® (natamycin ophthalmic suspension) 5%, an ocular antifungal drug for topical administration.

As part of the agreement, the marketing authorisations for NATACYN® will be transferred to Clinigen or Clinigen appointed partners in Argentina, Colombia, Botswana, Mauritius, South Africa, Hong Kong, Thailand, Malaysia, Singapore and Taiwan for commercial product supply. In all other territories, excluding the US and China and Thailand, Clinigen will provide physicians and pharmacists with access to NATACYN® on an unlicensed basis.

Under the terms of the agreement Clinigen will manage all elements of the program including healthcare practitioner enquiry management, regulatory oversight, logistics and access management.

Sam Herbert, Chief Operating Officer and Head of Products Division, Clinigen, said:

"We look forward to working with Eyevance to make NATACYN® available to healthcare professionals. NATACYN® is an important medicine, as demonstrated by its status as an Essential Medicine by the World Health Organization.

"This agreement demonstrates the value of our lifecycle platform and our commitment in partnering with pharmaceutical companies to provide physicians and pharmacists around the world with access to important medicines that improve the quality of patients' lives."

Contact details

Clinigen Group plc
Sam Herbert,
Group Chief Operating Officer & Head of Products Division
+44 (0) 1283 495010

Consilium Strategic Communications
Mary-Jane Elliott / Matthew Cole / Matthew Neal
Tel: +44 (0) 20 3709 5700

Notes to Editors

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global, specialist pharmaceutical Services and Products company focused on providing ethical access to medicines. Its' mission is to deliver the right medicine to the right patient at the right time. The Group operates from sites in North America, Europe, Africa and the Asia Pacific.

Clinigen has more than 1,000 employees across five continents in 16 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 34 of the top 50 pharmaceutical companies; interacting with over 5,000 hospitals across more than 115 countries.

For more information on Clinigen, please visit

About Eyevance Pharmaceuticals

Eyevance Pharmaceuticals is a Fort Worth-based company committed to developing and commercializing innovative and impactful ophthalmic products that enable optimal vision and better quality of life for all patients. Eyevance seeks to establish a portfolio of products that address significant unmet needs, including rare and orphan conditions, while also focusing on products with a legacy of proven safety and efficacy. For more information, visit

About NATACYN®(natamycin ophthalmic suspension)

NATACYN® (natamycin ophthalmic suspension) 5% is a topical ocular antifungal, indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including Fusarium solani keratitis. NATACYN® is the only FDA-approved topical ocular antifungal drug and is on the World Health Organization's List of Essential Medicines.

About Santen

As a global specialized company dedicated to ophthalmology, Santen brings a 130-year history of scientific knowledge and organizational capabilities to research, development, and commercialization of pharmaceuticals, surgical and medical devices, and OTC eye-care products. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now reach patients in more than 60 countries. Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society. For more information, please visit Santen's websites and (Japan headquarters).